Determining the context specificity of metformin treatment on muscle mitochondria and healthspan

Active Project Grant Awarded Last action

Award ID
R01AG074502
Recipient
Awarding agency
Obligated
$7,744,998

Award facts

Assistance listing
93.866 Aging Research
Completion date 96% complete
Place of performance
Oklahoma City, OK 73104, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Metformin, the most widely prescribed medication for treating type 2 diabetes, is increasingly recognized for healthspan effects that resemble exercise. The beneficial effects of metformin, like aerobic exercise, appear to be mediated through an energetic and/or redox stress mechanism, raising the prospect that the two approaches could exert additive or even synergistic effects. Surprisingly, our recently published clinical trial showed that metformin inhibits the beneficial effects of aerobic exercise training (AET) on skeletal muscle mitochondrial function and whole-body insulin sensitivity. Interestingly, subjects who entered the study with the highest mitochondrial complex i supported oxphos function and insulin sensitivity were the most negatively affected by metformin treatment. How metformin inhibits the positive effects of AET, why this effect is most pronounced in those with the highest mitochondrial function, and how these interactions ultimately impact healthspan and lifespan are unknown. The hypothesis of this proposal is that the effects of metformin on healthspan and lifespan are context specific; beneficial in the context of low energy demand/mitochondrial capacity but detrimental in the context of high energy demand/mitochondrial capacity. To test this hypothesis, the study will leverage a RAT model with divergent selection for intrinsic aerobic capacity, referred to as high capacity and low capacity runners (HCR/LCR). By selecting for maximal treadmill running capacity, LCR and HCR rats diverged in intrinsic mitochondrial function, lifespan and metabolic traits that increase or decrease risk for chronic disease. Changes in mitochondrial function will be assessed using EX vivo respirometry that measures the interplay among three thermodynamic forces. Further, the proposal uses targeted kinetic and quantitative mitochondrial proteomics to understand appropriate or aberrant cellular remodeling, and novel in vivo imaging approaches to understand changes in mitochondrial morphology and dynamics. The specific aims are to: 1) establish if mitochondrial changes to metformin treatment are context specific, 2) establish if the effects of metformin on adaptations to aerobic exercise training are context specific, and 3) determine whether the beneficial effects of metformin on healthspan and lifespan are context specific. IT is expected that with metformin treatment, remodeling of mitochondria will be consistent with improved outcomes in LCR rats, but have no effect or will be detrimental in HCR, with or without exercise training. Further IT is expected that metformin will extend healthspan and lifespan in LCR rats, but not HCR rats. Successful completion of these aims will reveal the importance of context specificity on metformin action and the mechanisms underlying its positive and potentially negative impacts on healthspan and lifespan. This information is critical given the ever expanding off-target use of metformin in healthy individuals without chronic disease and/or overt metabolic dysfunction. Results from this project will help inform who can benefit from metformin treatment, and more importantly, who should avoid IT.

Transactions

Action Obligated Date
Amendment $58,897
Amendment $530,077
Amendment $530,077
Amendment $47,691
Amendment $47,691
Amendment $47,691
Amendment $0
Amendment $0
Amendment $0
Amendment $536,527
Amendment $536,527
Amendment $536,527
Amendment $60,822
Amendment $60,822
Amendment $547,403
Amendment $547,403
Amendment $547,403
Amendment $614,408
Amendment $614,408
Amendment $614,408
Amendment $614,408
Original award $651,808
Show all 22

Subawards

Subrecipient Amount Awarded
University Of Toledo Dr. Koch's group will be responsible for conducting selective breeding for LCR HCR rats, validate exercise phenotypes by testing offspring for intrinsic… $43,522
Wake Forest University Health Sciences Dr. Neufer will work directly with Dr. Miller to ensure the successful incorporation of the force-flow creatine kinase respiratory clamp and P/O assays… $25,401
University Of Toledo Dr. Koch will be responsible for developing and providing the rat models to address the main purpose of this grant – to understand the positive and negative… $42,651
Wake Forest University Health Sciences Dr. Neufer will work directly with Dr. Miller to ensure the successful incorporation of the force-flow creatine kinase respiratory clamp and P/O assays… $45,269
University Of Toledo Dr. Koch will be responsible for developing and providing the rat models to address the main purpose of this grant – to understand the positive and… $43,522
East Carolina University Drs. Neufer and Lin will be responsible for ensuring the successful incorporation of advanced mitochondrial function analysis (force-flow, proton conductance,… $5,025
University Of Toledo Dr. Koch will be responsible for developing and providing the rat models to address the main purpose of this grant – to understand the positive and… $53,199
East Carolina University Drs. Neufer and Lin will be responsible for ensuring the successful incorporation of advanced mitochondrial function analysis (force-flow, proton conductance,… $50,401

Quick answers

Who received award R01AG074502?

R01AG074502 was awarded to Oklahoma Medical Research Foundation by National Institute on Aging (National Institutes of Health) on April 1, 2022.

How much is award R01AG074502 worth?

$7,744,998 has been obligated on R01AG074502.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login